EntryPoint Capital LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

EntryPoint Capital LLC purchased a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,535 shares of the company’s stock, valued at approximately $183,000.

Other institutional investors have also made changes to their positions in the company. Emerald Advisers LLC lifted its position in Keros Therapeutics by 57.3% in the 4th quarter. Emerald Advisers LLC now owns 244,633 shares of the company’s stock worth $3,873,000 after buying an additional 89,088 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock worth $30,981,000 after acquiring an additional 100,691 shares during the last quarter. Fox Run Management L.L.C. raised its holdings in shares of Keros Therapeutics by 261.5% during the fourth quarter. Fox Run Management L.L.C. now owns 22,213 shares of the company’s stock worth $352,000 after acquiring an additional 16,069 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Keros Therapeutics during the fourth quarter valued at $90,000. Finally, American Century Companies Inc. grew its stake in Keros Therapeutics by 10.5% in the fourth quarter. American Century Companies Inc. now owns 328,920 shares of the company’s stock valued at $5,207,000 after purchasing an additional 31,251 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KROS shares. Scotiabank reduced their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. Truist Financial reduced their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Finally, Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Price Performance

KROS stock opened at $10.79 on Friday. The stock has a market capitalization of $437.66 million, a price-to-earnings ratio of -2.07 and a beta of 1.39. The company has a 50-day moving average of $11.15 and a two-hundred day moving average of $34.44. Keros Therapeutics, Inc. has a 52-week low of $9.78 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Equities analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.